Trevi Therapeutics Stock Investor Sentiment

TRVI Stock  USD 2.82  0.06  2.08%   
Under 66% of Trevi Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Trevi Therapeutics stock suggests that many investors are alarmed at this time. Trevi Therapeutics' investing sentiment shows overall attitude of investors towards Trevi Therapeutics.
  

Trevi Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Trevi Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a month ago at finance.yahoo.com         
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Yahoo News
over a month ago at gurufocus.com         
Trevi Therapeutics Inc Q2 2024 Earnings Call Highlights Navigating Financial Challenges ...
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Trevi Therapeutics Buy Rating Reaffirmed at B. Riley - MarketBeat
Google News at Macroaxis
over a month ago at news.google.com         
Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs - Marketscreener.com
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Trevi Therapeutics Provides Update on Haduvios Clinical Development Program
Yahoo News
over a month ago at news.google.com         
Trevi Therapeutics Announces Executive Team Changes and Haduvio Progress - TipRanks
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
Yahoo News
over a month ago at finance.yahoo.com         
Acquisition by James Cassella of 400000 shares of Trevi Therapeutics at 3.34 subject to Rule 16b-3
Yahoo News
over two months ago at simplywall.st         
We Think Trevi Therapeutics Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over two months ago at finance.yahoo.com         
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted...
Yahoo News
over two months ago at news.google.com         
Trevi Therapeutics, Inc. Given Average Rating of Buy by Analysts - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 202...
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of 1840 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Disposition of 4219 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
Macroaxis News
over two months ago at news.google.com         
Disposition of 40277 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Trevi Therapeutics that are available to investors today. That information is available publicly through Trevi media outlets and privately through word of mouth or via Trevi internal channels. However, regardless of the origin, that massive amount of Trevi data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Trevi Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Trevi Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Trevi Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Trevi Therapeutics alpha.

Trevi Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 4219 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/06/2024
2
Disposition of 1840 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3
09/09/2024
3
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
09/26/2024
4
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
09/30/2024
5
Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs - Marketscreener.com
10/04/2024
6
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
10/15/2024
7
Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.
10/23/2024
8
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/06/2024
9
Trevi Therapeutics, Inc. Q3 2024 Earnings Call Transcript
11/08/2024
10
Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Quantisnow
11/14/2024

Complementary Tools for Trevi Stock analysis

When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals